Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy

Robert L. Murphy, Baiba Berzins, Carlos Zala, Carl Fichtenbaum, Michael P. Dube, Giovanni Guaraldi, Francesca Torriani, Elizabeth Belsey, Carol Mitchell, James H. Stein

Research output: Contribution to journalArticlepeer-review

39 Scopus citations

Abstract

Objective: Protease inhibitors and other antiretroviral drugs have been associated with dyslipidemia, endothelial dysfunction, and increased cardiovascular disease risk. The protease inhibitor atazanavir has an advantageous lipid profile; we studied its effects on arterial function and other metabolic and inflammatory cardiovascular disease risk factors. Design: Prospective, randomized, multinational trial in HIV-infected patients receiving stable protease inhibitor-based therapy with plasma HIV RNA less than 500 copies/ml and fasting low-density lipoprotein cholesterol more than 130 mg/dl, or triglycerides more than 200 mg/dl. Methods: Patients were randomized to continue their current protease inhibitor or switch the protease inhibitor to atazanavir and continue ritonavir if given as a protease inhibitor booster for 24 weeks. Brachial artery flow-mediated dilation, lipoproteins, and inflammatory and metabolic markers were measured at baseline, week 12, and week 24. Median changes within (signed rank test) and between (Wilcoxon test) arms were calculated. Results: Twenty-six patients switched to atazanavir (all continued on ritonavir); 24 remained on their protease inhibitor regimen. Median CD4 cell count was 499 cells/μl, total cholesterol 204 mg/dl, low-density lipoprotein cholesterol 122 mg/dl, and triglycerides 244 mg/dl. There were no significant changes in flow-mediated dilation after 12 and 24 weeks. At 24 weeks, significant changes in the atazanavir vs. continued protease inhibitor group were observed for total cholesterol (-25 vs. +1.5 mg/dl, P = 0.009), triglycerides (-58 vs. +3.5 mg/dl, P = 0.013), and nonhigh-density lipoprotein cholesterol (-27 vs.-0.5 mg/dl, P = 0.014). Conclusion: In dyslipidemic individuals with suppressed HIV RNA on stable therapy, changing the protease inhibitor to atazanavir/ritonavir for 24 weeks improved lipids; however, endothelial function, inflammatory, and metabolic markers did not change.

Original languageEnglish (US)
Pages (from-to)885-890
Number of pages6
JournalAIDS
Volume24
Issue number6
DOIs
StatePublished - Mar 2010

Keywords

  • Atazanavir
  • Cardiovascular risk
  • Endothelial function
  • HIV infection
  • Hyperlipidemia
  • Protease inhibitors

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy'. Together they form a unique fingerprint.

Cite this